Clinician, involved since 1982 in the fight against HIV infection, my clinical research has been on characterization and evolution of clinical presentation and therapeutic strategies in various severe and transmissible diseases, mainly HIV and infective endocarditis. From the experience with HIV infected patients, I have been concerned with the mandatory interdisciplinary collaboration for research on emerging infectious diseases (new forms of already known or new infectious diseases), especially between bio-medical and human and social sciences researchers (as applied to vancomycin-resistant enterococcal infections, influenza, dengue fever). Since 2009, I have moved from a patient’s focused approach of research to the collective dimension of infectious diseases, and a more public-health-oriented research. In the context of my double mission of teaching and research, a special effort has been made to use large research clinical studies for training of students to clinical research.

2021

Ben Hayoun M, Tubiana S, Varon E, Naccache JM, Le Floch H, Leport C, Claessens YE, Duval X, PEsg
2010 French SPILF-AFSSAPS guiding criteria for Streptococcuspneumoniae acute community-acquired pneumonia: Evaluation in patients of the PACSCAN-ESCAPED cohort.
Infectious Diseases Now 2021, 52, 146-152.

2020

Loubet P, Tubiana S, Claessens Y, Epelboin L, Ficko C, Le Bel J, Rammaert B, Garin N, Prendki V, Stirnemann J, Leport C, Yazdanpanah Y, Varon E, Duval X, Claessens Y, Duval X, Bouvard E, Carette M, Debray M, Mayaud C, Leport C, Houhou N, Tubiana S, Benjoar M, Blanc F, Brun A, Epelboin L, Ficko C, Khalil A, Lefloch H, Naccache J, Rammaert B, Abry A, Allo J, Andre S, Andreotti C, Baarir N, Bendahou M, Benlafia L, Bernard J, Berthoumieu A, Billemont M, Bokobza J, Brun A, Burggraff E, Canavaggio P, Carette M, Casalino E, Castro S, Choquet C, Clément H, Colosi L, Dabreteau A, Damelincourt S, Dautheville S, Debray M, Delay M, Delerme S, Depierre L, Djamouri F, Dumas F, Fadel M, Feydey A, Freund Y, Garcia L, Goulet H, Hausfater P, Ilic-Habensus E, Josse M, Kansao J, Kieffer Y, Lecomte F, Lemkarane K, Madonna P, Meyniard O, Mzabi L, Pariente D, Pernet J, Perruche F, Piquet J, Ranerison R, Ray P, Renai F, Rouff E, Saget D, Saïdi K, Sauvin G, Trabattoni E, Trimech N, Auger C, Pasquet B, Tamazirt S, Treluyer J, Tubach F, Wang J, Chassany O, Misse C
Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication.
Clinical Microbiology and Infection 2020, 26, 382.e1-382.e7.

Le Turnier P, Leport C, Martin P, Jadand C, Hoen B, Guégan JF
Multi-sectorial research is paramount for preventing and controlling emerging infectious diseases.
Revue D'epidemiologie Et De Sante Publique 2020, 68, 133-136.

Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, ACACSG
Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
AIDS research and human retroviruses 2020, 36, 399-405.

Roux P, Josselin LB, Grall N, Dumonceau O, Leport C
[Recurrent urinary tract infections in men: how to avoid antibiotics].
La Revue Du Praticien 2020, 70, 1053-1057.

2019

Bastard JP, Couffignal C, Fellahi S, Bard JM, Mentre F, Salmon D, Katlama C, Raffi F, Leport C, Capeau J, ACACCsg
Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.
Diabetes & Metabolism 2019, 45, 573-581.

Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C
Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1389-1394.

Landon-Cardinal O, Gallay L, Dubourg O, Maisonobe T, Léonard-Louis S, Beniken D, Simon A, Behin A, Stojkovic T, Duyckaerts C, Breton G, Rigolet A, Fain O, Meyohas MC, Leport C, Valantin MA, Vittecoq D, Bergmann JF, Hanslik T, Chauveheid MP, Amoura Z, de Broucker T, Eymard B, Beaudequin N, Benveniste O, Allenbach Y
Expanding the spectrum of HIV-associated myopathy.
Journal of Neurology, Neurosurgery, and Psychiatry 2019, 90, 1296-1298.

Le Tyrant M, Bley D, Leport C, Alfandari S, Guégan JF
Low to medium-low risk perception for dengue, chikungunya and Zika outbreaks by infectious diseases physicians in France, Western Europe.
BMC public health 2019, 19, 1014.

2018

Coignard-Biehler H, Rapp C, Chapplain JM, Hoen B, Che D, Berthelot P, Cazenave-Roblot F, Rabaud C, Brouqui P, Leport C, SCEg
The French Infectious Diseases Society's readiness and response to epidemic or biological risk-the current situation following the Middle East respiratory syndrome coronavirus and Ebola virus disease alerts.
Medecine Et Maladies Infectieuses 2018, 48, 95-102.

Burdet C, Guegan JF, Duval X, Le Tyrant M, Bergeron H, Manuguerra JC, Raude J, Leport C, Zylberman P
Need for integrative thinking to fight against emerging infectious diseases. Proceedings of the 5th seminar on emerging infectious diseases, March 22, 2016 - current trends and proposals.
Rev Epidemiol Sante Publique 2018, 66, 81-90.

Flateau C, Le Bel J, Tubiana S, Blanc FX, Choquet C, Rammaert B, Ray P, Rapp C, Ficko C, Leport C, Claessens YE, Duval X, Esg
High heterogeneity in community-acquired pneumonia inclusion criteria: does this impact on the validity of the results of randomized controlled trials?.
BMC infectious diseases 2018, 18, 607.

Rasigade JP, Leclère A, Alla F, Tessier A, Bes M, Lechiche C, Vernet-Garnier V, Laouénan C, Vandenesch F, Leport C, ASG
Staphylococcus aureus CC30 Lineage and Absence of sed,j,r-Harboring Plasmid Predict Embolism in Infective Endocarditis.
Frontiers in Cellular and Infection Microbiology 2018, 8, 187.

2017

Préau M, Laguette V, March L, Rabaud C, Hardel L, Protopopescu C, Granier P, Pierret J, Leport C, Raffi F, ACACSG
Discussing HIV Status: Is It Easier After 10 Years of Antiretroviral Treatment? The ANRS CO8 APROCO-COPILOTE Cohort.
AIDS and behavior 2017, 21, 118-128.

Raffi F, Le Moing V, Assuied A, Habak S, Spire B, Cazanave C, Billaud E, Dellamonica P, Ferry T, Fagard C, Leport C, ACCSG
Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course.
The Journal of Antimicrobial Chemotherapy 2017, 72, 240-245.

Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S, CiEaASG
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2869-2878.

Protopopescu C, Carrieri MP, Raffi F, Picard O, Hardel L, Piroth L, Jadand C, Pierret J, Spire B, Leport C, ACACSG
Brief Report: Prolonged Viral Suppression Over a 12-Year Follow-up of HIV-Infected Patients: The Persistent Impact of Adherence at 4 Months After Initiation of Combined Antiretroviral Therapy in the ANRS CO8 APROCO-COPILOTE Cohort.
Journal of Acquired Immune Deficiency Syndromes (1999) 2017, 74, 293-297.

Flicoteaux R, Protopopescu C, Tibi A, Blanchon T, Werf SVD, Duval X, Mosnier A, Charlois-Ou C, Lina B, Leport C, Chevret S
Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial.
BMJ open 2017, 7, e014546.

2016

Guégan JF, Zylberman P, Le Tyrant M, Che D, Bergeron H, Meynard JB, Leport C, scot4VdGsoeid
Proceedings of the 4th School of Val-de-Grâce's seminar on emerging infectious diseases. Current trends and proposals, March 2015, 25th.
Medecine Et Maladies Infectieuses 2016, 46, 333–341.

Hema MN, Ferry T, Dupon M, Cuzin L, Verdon R, Thiébaut R, Protopopescu C, Leport C, Raffi F, Le Moing V, AC8(sg
Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study.
PloS One 2016, 11, e0161594.

2015

Das D, Le Floch H, Houhou N, Epelboin L, Hausfater P, Khalil A, Ray P, Duval X, Claessens YE, Leport C, ESG
Viruses detected by systematic multiplex polymerase chain reaction in adults with suspected community-acquired pneumonia attending emergency departments in France.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2015, 21, 608.e1–8.

Leport C, Coignard H, Diehl JL
Organizing the French response to the Ebola virus infection in West Africa - ethical considerations on information given to patients, their relatives, and healthcare professionals.
Medecine Et Maladies Infectieuses 2015, 45, 109–110.

Bastard JP, Fellahi S, Couffignal C, Raffi F, Gras G, Hardel L, Sobel A, Leport C, Fardet L, Capeau J, ACACCSG
Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1816-1824.

Chirouze C, Journot V, Le Moing V, Raffi F, Piroth L, Reigadas S, Cassuto JP, Chêne G, Leport C, Hoen B, AC0ACSG
Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
Journal of Acquired Immune Deficiency Syndromes (1999) 2015, 68, 204–208.

Claessens YE, Debray MP, Tubach F, Brun AL, Rammaert B, Hausfater P, Naccache JM, Ray P, Choquet C, Carette MF, Mayaud C, Leport C, Duval X
Early Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia.
American Journal of Respiratory and Critical Care Medicine 2015, 192, 974-982.

Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, Merson L, AlJohani S, Al-Khairy K, Carson G, Luke TC, Hensley L, Al-Dawood A, Al-Qahtani S, Modjarrad K, Sadat M, Rohde G, Leport C, Fowler R
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.
SpringerPlus 2015, 4, 709.

LpwgiCiE, Mocroft A, Lundgren J, Antinori A, Monforte Ad, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2015, 20,

Blanchon T, Geffrier F, Turbelin C, Daviaud I, Laouénan C, Duval X, Lambert B, Hanslik T, Mosnier A, Leport C
Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
Antiviral Therapy 2015, 20, 753–761.

Protopopescu C, Raffi F, Spire B, Hardel L, Michelet C, Cheneau C, Le Moing V, Leport C, Carrieri MP, ACACSG
Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort.
Antiviral Therapy 2015, 20, 763-772.

2014

Flicoteaux R, Pulcini C, Carrieri P, Schwarzinger M, Leport C, Verger P
Correlates of general practitioners' recommendations to patients regarding vaccination for the 2009-2010 pandemic influenza (A/H1N1) in France: implications for future vaccination campaigns.
Vaccine 2014, 32, 2281-2287.

Carrieri MP, Protopopescu C, Raffi F, March L, Reboud P, Spire B, Leport C, ACACSG
Low alcohol consumption as a predictor of higher CD4+ cell count in HIV-treated patients: a french paradox or a proxy of healthy behaviors? The ANRS APROCO-COPILOTE CO-08 cohort.
Journal of Acquired Immune Deficiency Syndromes (1999) 2014, 65, e148–150.

Bonduelle O, Carrat F, Luyt CE, Leport C, Mosnier A, Benhabiles N, Krivine A, Rozenberg F, Yahia N, Samri A, Rousset D, van der Werf S, Autran B, Combadiere B
Characterization of pandemic influenza immune memory signature after vaccination or infection.
The Journal of Clinical Investigation 2014, 124, 3129–3136.

Leport C, Zylberman P, Guégan JF, Bricaire F, Cavallo JD, Che D, Eliaszewicz M, Moatti JP
Proceedings of the 2nd seminar on emerging infectious diseases, December 7, 2012 – Current trends and proposals.
Revue D'epidemiologie Et De Sante Publique 2014, 62, 153–158.

2013

Ploin D, Chidiac C, Carrat F, Cohen B, Javouhey E, Mayaud C, Desenclos JC, Lina B, Leport C, Fsg
Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections–the Fluco French cohort.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2013, 58, 114–119.

Bobin-Dubigeon C, Biron C, Volteau C, Piroth L, Biron A, Perré P, Leport C, Prazuck T, Sébille-Rivain V, Raffi F, Bard JM
Short communication: Paraoxonase 1 (PON1) in French HIV-infected patients under antiretroviral therapy: relationship with the metabolic syndrome and inflammation.
AIDS research and human retroviruses 2013, 29, 1571–1574.

Blanchon T, Mentré F, Charlois-Ou C, Dornic Q, Mosnier A, Bouscambert M, Carrat F, Duval X, Enouf V, Leport C, BSG
Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2013, 19, 196–203.

Goulenok T, Klein I, Mazighi M, Messika-Zeitoun D, Alexandra JF, Mourvillier B, Laissy JP, Leport C, Iung B, Duval X, Isg
Infective endocarditis with symptomatic cerebral complications: contribution of cerebral magnetic resonance imaging.
Cerebrovascular Diseases (Basel, Switzerland) 2013, 35, 327-336.

Iung B, Tubiana S, Klein I, Messika-Zeitoun D, Brochet E, Lepage L, Al-Attar N, Ruimy R, Leport C, Wolff M, Duval X, EISG
Determinants of cerebral lesions in endocarditis on systematic cerebral magnetic resonance imaging: a prospective study.
Stroke 2013, 44, 3056–3062.

Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Leport C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O, CoOHERE(siE
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
PLoS medicine 2013, 10, e1001510.

2012

Escuret V, Cornu C, Boutitie F, Enouf V, Mosnier A, Bouscambert-Duchamp M, Gaillard S, Duval X, Blanchon T, Leport C, Gueyffier F, Van Der Werf S, Lina B
Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Antiviral Research 2012, 96, 130–137.

Leport C, Guégan JF, Zylberman P, Bitar D, Bricaire F, Cavallo JD, Eliaszewicz M, Moatti JP
Proceedings of the seminar on Emerging Infectious Diseases, November 9, 2011: current trends and proposals.
Médecine Et Maladies Infectieuses 2012, 42, 569–573.

Préau M, Protopopescu C, Raffi F, Rey D, Chêne G, Marcellin F, Perronne C, Ragnaud JM, Leport C, Spire B, ACACSG
Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability.
AIDS care 2012, 24, 434-443.

Nazih H, Raffi F, Taïeb A, Reynes J, Choutet P, Cassuto JP, Ferry T, Chêne G, Leport C, Bard JM, ACAC0SG
Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study.
AIDS research and human retroviruses 2012, 28, 393–399.

Biron A, Bobin-Dubigeon C, Volteau C, Piroth L, Perré P, Leport C, Prazuck T, Jovelin T, Billard M, Sébille V, Bard JM, Raffi F, Biron C
Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.
AIDS research and human retroviruses 2012, 28, 1672–1678.

CoOHERE(iE, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
International Journal of Epidemiology 2012, 41, 433-445.

Lamiraud K, Moatti JP, Raffi F, Carrieri MP, Protopopescu C, Michelet C, Schneider L, Collin F, Leport C, Spire B
Adherence to and effectiveness of highly active antiretroviral treatment for HIV infection: assessing the bidirectional relationship.
Medical Care 2012, 50, 410–418.

Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chêne G, ACACCSG
Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.
AIDS (London, England) 2012, 26, 303-314.

Carrieri MP, Protopopescu C, Le Moing V, Reboud P, Raffi F, Mahy S, Roux P, Cuzin L, Spire B, Leport C, SCACSG
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy.
BMJ open 2012

Protopopescu C, Raffi F, Brunet-François C, Salmon D, Verdon R, Reboud P, Carrieri MP, Leport C, Spire B, Michel L, AC(CSG
Incidence, medical and socio-behavioural predictors of psychiatric events in an 11-year follow-up of HIV-infected patients on antiretroviral therapy.
Antiviral Therapy 2012, 17, 1079-1083.

Carrat F, Duval X, Tubach F, Mosnier A, Van der Werf S, Tibi A, Blanchon T, Leport C, Flahault A, Mentré F, Bsg
Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households.
Antiviral Therapy 2012, 17, 1085–1090.

Guiyedi V, Mounoury O, Boucherit S, Longuet P, Brunet-François C, Kendjo E, Ecobichon JL, Okome-Nkoumou M, Leport C, Raffi F
Optimized Antiretroviral Therapy with Darunavir/Ritonavir, Etravirine and/or Raltegarvir: A Salvage Therapy Option in HIV-1 Infected Patients with Long-Term Therapeutic Failures, about 23 Cases.
World Journal of AIDS 2012, 02, 300–305.

Breton G, Bourgarit A, Pavy S, Bonnet D, Martinez V, Duval X, Longuet P, Abgrall S, Simon A, Leport C, PTSG
Treatment for tuberculosis-associated immune reconstitution inflammatory syndrome in 34 HIV-infected patients.
The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease 2012, 16, 1365-1370.

Leport C
[Is infective endocarditis prophylaxis always recommended?].
La Revue Du Praticien 2012, 62, 515–517.

2011

Franrenet S, Moutel G, Raffi F, Dabis F, Bruyand M, Hervé C, Leport C, Duchange N
Information that should be given to HIV cohort participants during ongoing research: the viewpoints of patient representatives and research professionals.
Journal of empirical research on human research ethics: JERHRE 2011, 6, 76-83.

2010

Hekimian G, Kim M, Passefort S, Duval X, Wolff M, Leport C, Leplat C, Steg G, Iung B, Vahanian A, Messika-Zeitoun D
Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis.
Heart (British Cardiac Society) 2010, 96, 696-700.

Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentré F, Leport C, BSG
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
PLoS medicine 2010, 7, e1000362.

Duval X, Iung B, Klein I, Brochet E, Thabut G, Arnoult F, Lepage L, Laissy JP, Wolff M, Leport C, I(MIatAPoESG
Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study.
Annals of Internal Medicine 2010, 152, 497-504, W175.

2009

Klein I, Iung B, Labreuche J, Hess A, Wolff M, Messika-Zeitoun D, Lavallée P, Laissy JP, Leport C, Duval X, ISG
Cerebral microbleeds are frequent in infective endocarditis: a case-control study.
Stroke 2009, 40, 3461-3465.

2008

Duval X, Gallien S, Leport C
[What is the state of infective endocarditis prophylaxis guidelines according to the latest American recommendations?].
Medecine Et Maladies Infectieuses 2008, 38 Suppl 2, S52-54.

Duval X, Leport C
Prophylaxis of infective endocarditis: current tendencies, continuing controversies.
The Lancet. Infectious Diseases 2008, 8, 225-232.

Duval X, Leport C, Danchin N
The new American Heart Association guidelines on the prevention of infective endocarditis: culmination of a long process of thought.
Heart (British Cardiac Society) 2008, 94, 715-716.

Duval X, Baron G, Garelik D, Villes V, Dupré T, Leport C, Lert F, Peretti-Watel P, Ravaud P, Spire B, ESG
Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study.
Antiviral Therapy 2008, 13, 389-397.

2007

Duval X, Alla F, Doco-Lecompte T, Le Moing V, Delahaye F, Mainardi JL, Plesiat P, Célard M, Hoen B, Leport C, AplelPdlI(
Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality.
European Heart Journal 2007, 28, 59-64.

Duval X, Peytavin G, Breton G, Ecobichon JL, Descamps D, Thabut G, Leport C
Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.
AIDS (London, England) 2007, 21, 106-108.

Abramowitz L, Benabderrahmane D, Ravaud P, Walker F, Rioux C, Jestin C, Bouvet E, Soulé JC, Leport C, Duval X
Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors.
AIDS (London, England) 2007, 21, 1457-1465.

Essig M, Duval X, Kaied FA, Iordache L, Gervais A, Longuet P, Blanchet F, Peytavin G, Leport C
Is phosphatemia the best tool to monitor renal tenofovir toxicity?.
Journal of Acquired Immune Deficiency Syndromes (1999) 2007, 46, 256-258.

2006

Duval X, Alla F, Hoen B, Danielou F, Larrieu S, Delahaye F, Leport C, Briançon S
Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2006, 42, e102-107.

Berki-Benhaddad Z, Ecobichon JL, Mentré F, Capillon A, Certain A, Secondi C, Gervais A, Longuet P, Vildé JL, Leport C
[Adherence intervention for HIV-infected patients receiving antiretroviral treatment. Implementation and initial assessment].
Presse Médicale (Paris, France: 1983) 2006, 35, 1241-1248.

2005

Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, Duval X, Dereuddre-Bosquet N, Clayette P, Sterkers G, Simon A, Ameisen JC, Leport C
Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
The Journal of Infectious Diseases 2005, 191, 1670-1679.

Danchin N, Duval X, Leport C
Prophylaxis of infective endocarditis: French recommendations 2002.
Heart (British Cardiac Society) 2005, 91, 715-718.

Duval X, Mentré F, Lamotte C, Chêne G, Spire B, Dellamonica P, Panhard X, Salmon D, Raffi F, Peytavin G, Leport C, ASG
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
Therapeutic Drug Monitoring 2005, 27, 63-70.

Duval X, Descamps D, Breton G, Darmon S, Ecobichon JL, Delarue S, Peytavin G, Leport C, Vildé JL, Brun-Vézinet F
Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
Antiviral Therapy 2005, 10, 197-199.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM, CA1SG
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Clinical Pharmacokinetics 2005, 44, 1267-1278.

2004

Breton G, Alexandre M, Duval X, Prie D, Peytavin G, Leport C, Vildei JL
Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Scandinavian Journal of Infectious Diseases 2004, 36, 527-528.

Duval X, Selton-Suty C, Alla F, Salvador-Mazenq M, Bernard Y, Weber M, Lacassin F, Nazeyrolas P, Chidiac C, Hoen B, Leport C, AplelPdlI
Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2004, 39, 68-74.

Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F, AC(SG
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2004, 39, 248-255.

Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, Longuet P, Leport C, Vildé JL
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2004, 39, 1709-1712.

Breton G, Bouldouyre MA, Gervais A, Duval X, Longuet P, Leport C, Vildé JL
Failure of valacyclovir for herpes zoster in a moderately immunocompromised HIV-infected patient.
AIDS patient care and STDs 2004, 18, 255-257.

Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
HIV medicine 2004, 5, 307-313.

Selton-Suty C, Duval X, Brochet E, Doco-Lecompte T, Hoen B, Delahaye E, Leport C, Danchin N
[New French recommendations for the prophylaxis of infectious endocarditis].
Archives Des Maladies Du Coeur Et Des Vaisseaux 2004, 97, 626-631.

Duval X, Pajot O, Le Moing V, Longuet P, Ecobichon JL, Mentre F, Leport C, Vilde JL
Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy.
AIDS (London, England) 2004, 18, 1342-1344.

2003

Breton G, Duval X, Gervais A, Longuet P, Leport C, Vildé JL
Retroviral rebound syndrome with meningoencephalitis after cessation of antiretroviral therapy.
The American Journal of Medicine 2003, 114, 769-770.

2002

Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Antimicrobial Agents and Chemotherapy 2002, 46, 570-574.

2001

Duval X, Larger E, Longuet P, Leport C, Vilde JL
Galactorrhoea, hyperprolactinaemia, and protease inhibitors.
Lancet (London, England) 2001, 357, 475.

Fidouh-Houhou N, Duval X, Bissuel F, Bourbonneux V, Flandre P, Ecobichon JL, Jordan MC, Vildé JL, Brun-Vézinet F, Leport C
Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2001, 33, 1406-1411.

Le Moing V, Eid Z, Ecobichon JL, Duval X, Longuet P, Elbim C, Brun-Vezinet F, Leport C, Vilde JL
[Long-term immunologic response in HIV-infected patients with CD4 cell counts Annales De Medecine Interne 2001, 152, 11-14.

Descamps V, Duval X, Grossin M, Crickx B, Leport C
Topical cidofovir for bowenoid papulosis in an HIV-infected patient.
The British Journal of Dermatology 2001, 144, 642-643.

Duval X, Papastamopoulos V, Longuet P, Benoit C, Perronne C, Leport C, Vildé JL
Definite streptococcus bovis endocarditis: characteristics in 20 patients.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2001, 7, 3-10.

Duval X, Djendli S, Le Moing V, Longuet P, Barry B, Leport C, Vildé JL
Recurrent Staphylococcus aureus extracerebral infections complicating hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber disease).
The American Journal of Medicine 2001, 110, 671-672.

Duval X, Trad S, Le Moing V, Longuet P, Leport C, Vildé JL
[Paradoxical aggravation of tuberculosis after antiretroviral therapy in HIV-infected patients].
Presse Medicale (Paris, France: 1983) 2001, 30, 213-216.

2000

Duval X, Le Moing V, Longuet C, Leport C, Vildé JL, Lamotte C, Peytavin G, Farinotti R
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
Antimicrobial Agents and Chemotherapy 2000, 44, 2593.

1999

Le Moing V, Lacassin F, Delahousse M, Duval X, Longuet P, Leport C, Vildé JL
Use of corticosteroids in glomerulonephritis related to infective endocarditis: three cases and review.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1999, 28, 1057-1061.

Benveniste O, Longuet P, Duval X, Le Moing V, Leport C, Vildé JL
Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1999, 28, 1180-1181.

François B, Duval X, Le Moing V, Bruneel F, Leport C, Vilde JL
[Bupivacaine-induced meningitis].
La Revue De Medecine Interne 1999, 20, 719-720.

Duval X, Peytavin G, Fouqueray B, Leport C, Vildé JL
Renin-angiotensin system inhibition in a patient having an overdose of HIV protease inhibitor.
AIDS (London, England) 1999, 13, 1983-1984.

Longuet P, Duval X, Le Moing V, Scanvic-Hameg A, Leport C, Vildé JL
[Antibiotic prophylaxis in patients at high risk of nosocomial outbreak of legionellosis].
Presse Medicale (Paris, France: 1983) 1999, 28, 1755-1756.

Leport C, Duval X
[Cerebral toxoplasmosis in an HIV-infected patient. Diagnosis, development, treatment and prevention].
La Revue Du Praticien 1999, 49, 2271-2274.

1995

Duval X, Paty MC, Longuet P, Lacassin F, Perronne C, Leport C, Vildé JL
[Pneumopathies caused by Streptococcus pneumoniae in 27 HIV infected patients].
Presse Medicale (Paris, France: 1983) 1995, 24, 715-718.

1988

Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, Vilde JL
Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.
The American Journal of Medicine 1988, 84, 94-100.